Population pharmacokinetic model for oral ORIN1001 in Chinese patients with advanced solid tumors

Background: ORIN1001, a first-in-class oral IRE1-α endoribonuclease inhibitor to block the activation of XBP1, is currently in clinical development for inhibiting tumor growth and enhancing the effect of chemical or targeted therapy. Early establishment of a population pharmacokinetic (PopPK) model...

Full description

Bibliographic Details
Main Authors: Xiaoqing Li, Yunhai Bo, Qingping Zeng, Lei Diao, Stephanie Greene, John Patterson, Lu Liu, Fen Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1322557/full